Results 171 to 180 of about 1,580 (184)

Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin

Proceedings of the National Academy of Sciences of the United States of America, 2018
John A Rohde, Osha Roopnarine, David D Thomas   +2 more
exaly  

Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM

JACC: Cardiovascular Imaging
David Fermín, Mark V Sherrid
exaly  

In vitroandin vivopharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin

Xenobiotica, 2019
James P Driscoll, Timothy J Carlson
exaly  

Mavacamten/sotalol

Reactions Weekly
openaire   +1 more source

Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten

Heart Rhythm
Matteo Castrichini, Said Alsidawi, Jeffrey B Geske   +2 more
exaly  

ICER assessing mavacamten for hypertrophic cardiomyopathy

PharmacoEconomics & Outcomes News, 2021
openaire   +1 more source

Mavacamten (▼Camzyos) for obstructive hypertrophic cardiomyopathy

Drug and Therapeutics Bulletin
openaire   +2 more sources

Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial

Circulation: Cardiovascular Imaging
Milind Y Desai, Yuichiro Okushi, Andrew Gaballa   +2 more
exaly  

Stop Dreaming: Mavacamten REMS Data Are Here

Circulation: Heart Failure
Ahmad Masri, Neal K. Lakdawala
openaire   +2 more sources

Drug–Drug Interaction Potential of Mavacamten with Midazolam: Combined Results from Clinical and Model‐Based Studies

Journal of Clinical Pharmacology
Samira Merali, Caroline Sychterz, Vidyā Perera   +2 more
exaly